<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1887-8571</journal-id>
<journal-title><![CDATA[Sanidad Militar]]></journal-title>
<abbrev-journal-title><![CDATA[Sanid. Mil.]]></abbrev-journal-title>
<issn>1887-8571</issn>
<publisher>
<publisher-name><![CDATA[Ministerio de Defensa]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1887-85712022000400010</article-id>
<article-id pub-id-type="doi">10.4321/s1887-857120220004000010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación positiva de medicamentos: julio, septiembre y octubre de 2022]]></article-title>
<article-title xml:lang="en"><![CDATA[Positive assessment of drugs: July, September and October of 2022]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Luque]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva-Cuevas]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Granda-Lobato]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Correa-Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacología Clínica ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacología Clínica ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>78</volume>
<numero>4</numero>
<fpage>261</fpage>
<lpage>267</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1887-85712022000400010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1887-85712022000400010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1887-85712022000400010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Europea del Medicamento, hechos públicos en julio, septiembre y octubre de 2022 y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY: The drugs assessed by the European Medicines Agency made public in July, September and October of 2022, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Abaloparatida (Eladynos®)]]></kwd>
<kwd lng="es"><![CDATA[Espesolimab (Spevigo®)]]></kwd>
<kwd lng="es"><![CDATA[Faricimab (Vabysmo®)]]></kwd>
<kwd lng="es"><![CDATA[Fosdenopterina (Nulibry®)]]></kwd>
<kwd lng="es"><![CDATA[Gozetotida (Locametz®)]]></kwd>
<kwd lng="es"><![CDATA[Loncastuximab tesirina (Zynlonta®)]]></kwd>
<kwd lng="es"><![CDATA[Maralixibat (Livmarli®)]]></kwd>
<kwd lng="es"><![CDATA[Maribavir (Livtencity®)]]></kwd>
<kwd lng="es"><![CDATA[Mitapivat (Pyrukynd®)]]></kwd>
<kwd lng="es"><![CDATA[Nirsevibab (Beyforuts®)]]></kwd>
<kwd lng="es"><![CDATA[Nivolumab/Relatlimab (Opdualag®)]]></kwd>
<kwd lng="es"><![CDATA[Sutimlimab (Enjaymo®)]]></kwd>
<kwd lng="es"><![CDATA[Tabelecleucel (Ebvallo®)]]></kwd>
<kwd lng="es"><![CDATA[Teclistamab (Tecvayli®)]]></kwd>
<kwd lng="es"><![CDATA[Tezepelumab (Tezspire®)]]></kwd>
<kwd lng="es"><![CDATA[Tirzepatida (Mounjaro®)]]></kwd>
<kwd lng="es"><![CDATA[Vacuna tetravalente contra el dengue (Qdenga®)]]></kwd>
<kwd lng="es"><![CDATA[Vipivotida tetraxetan lutecio (177LU) (Pluvicto®)]]></kwd>
<kwd lng="es"><![CDATA[Voclosporina (Lupkynis®)]]></kwd>
<kwd lng="es"><![CDATA[Vutrisiran (Amvuttra®)]]></kwd>
<kwd lng="en"><![CDATA[Abaloparatida (Eladynos®)]]></kwd>
<kwd lng="en"><![CDATA[Espesolimab (Spevigo®)]]></kwd>
<kwd lng="en"><![CDATA[Faricimab (Vabysmo®)]]></kwd>
<kwd lng="en"><![CDATA[Fosdenopterina (Nulibry®)]]></kwd>
<kwd lng="en"><![CDATA[Gozetotida (Locametz®)]]></kwd>
<kwd lng="en"><![CDATA[Loncastuximab tesirina (Zynlonta®)]]></kwd>
<kwd lng="en"><![CDATA[Maralixibat (Livmarli®)]]></kwd>
<kwd lng="en"><![CDATA[Maribavir (Livtencity®)]]></kwd>
<kwd lng="en"><![CDATA[Mitapivat (Pyrukynd®)]]></kwd>
<kwd lng="en"><![CDATA[Nirsevibab (Beyforuts®)]]></kwd>
<kwd lng="en"><![CDATA[Nivolumab/Relatlimab (Opdualag®)]]></kwd>
<kwd lng="en"><![CDATA[Sutimlimab (Enjaymo®)]]></kwd>
<kwd lng="en"><![CDATA[Tabelecleucel (Ebvallo®)]]></kwd>
<kwd lng="en"><![CDATA[Teclistamab (Tecvayli®)]]></kwd>
<kwd lng="en"><![CDATA[Tezepelumab (Tezspire®)]]></kwd>
<kwd lng="en"><![CDATA[Tirzepatida (Mounjaro®)]]></kwd>
<kwd lng="en"><![CDATA[Vacuna tetravalente contra el dengue (Qdenga ®)]]></kwd>
<kwd lng="en"><![CDATA[Vipivotida tetraxetan lutecio (177LU) (Pluvicto®)]]></kwd>
<kwd lng="en"><![CDATA[Voclosporina (Lupkynis®)]]></kwd>
<kwd lng="en"><![CDATA[Vutrisiran (Amvuttra ®)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="confpro">
<collab>AEMPS</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[EPAR-Refusal public assessment report of Eladynos®]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Eladynos®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Spevigo ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bachelez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Choon]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Marrakchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Burden]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trial of Spesolimab for Generalized Pustular Psoriasis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>385</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>2431-40</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baum]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Visvanathan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Garcet]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bossert]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2022</year>
<volume>149</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1402-12</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="confpro">
<collab>AEMPS</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>julio 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Vabysmo®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Nulibry®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Locametz ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zang]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[68 Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2021</year>
<volume>48</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>483-92</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hofman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Nzenza]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Herschtal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lourenco]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2018</year>
<volume>122</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>783-93</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="confpro">
<collab>AEMPS</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>septiembre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Zynlonta ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>septiembre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caimi]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Ai]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Alderuccio]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Ardeshna]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Hamdani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hess]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Loncastuximab tesirine in relapsed or refracory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2011</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>790-800</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gnanasakthy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ungar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life, symptoms, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse largeB-cell lymphoma]]></article-title>
<source><![CDATA[Clin Lymphoma Myeloma Leuk]]></source>
<year>2022</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>158-68</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de livmarli®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[EU/3/13/1214: Orphan designation for the treatment of Alagille syndrome]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<source><![CDATA[Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)]]></source>
<year></year>
<publisher-name><![CDATA[Clinicaltrials.gov]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>FDA</collab>
<source><![CDATA[Highlights of prescribing information for LIVMARLI]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maertens]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cordonnier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jaksch]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Poiré]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Uknis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maribavir for preemptive treatment of cytomegalovirus reactivation]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2019</year>
<volume>381</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1136-47</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avery]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Alain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Blumberg]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Chemaly]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Cordonnier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maribavir for refractory cytomegalovirus infectins with or without resistance post-transplant results from a phase 3 randomized clinical trial]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2022</year>
<volume>75</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>690-701</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Beyfortus ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>septiembre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Samkari]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Galactéros]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Glenthøj]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rothman]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Andres]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Grace]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitapivat versus placebo for pyruvate kinase deficiency]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>386</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1432-42</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glenthøj]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[van Beers]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Samkari]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Viprakasit]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[KHM]]></given-names>
</name>
<name>
<surname><![CDATA[Galactéros]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusines (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 tiral]]></article-title>
<source><![CDATA[Lancet Haematol]]></source>
<year>2022</year>
<volume>9</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>e724-32</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Beyfortus ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>septiembre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takas]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Domachowske]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Madhi]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Manzoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-Dose Nirsevimab for prevention of RSV en preterm infants]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2020</year>
<volume>383</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>415-25</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hammitt]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Dagan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Baca]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bosheva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Madhi]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nirsevimab for prevention of RSV in healthy late-preterm and term infants]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>386</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>837-46</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Nulibry®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Beyfortus ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>septiembre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Röth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barcellini]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[D'Sa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Miyakawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Broome]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Michel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sutimlimab in cold agglutinin disease]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2021</year>
<volume>384</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1323-34</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de ebvallo®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="book">
<source><![CDATA[Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy]]></source>
<year></year>
<publisher-name><![CDATA[Clinicaltrials.gov]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Tecvayli®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Tezspire®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de mounjaro®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wysham]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Frías]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Kaneko]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Landó]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Karanikas]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Thieu]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>398</volume>
<numero>10295</numero>
<issue>10295</issue>
<page-range>143-55</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chavda]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Ajabiya]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Teli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bojarska]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Apostolopoulos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2022</year>
<volume>27</volume>
<numero>13</numero>
<issue>13</issue>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="book">
<source><![CDATA[A Study of Tirzepatide (LY3298176) vs Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes]]></source>
<year></year>
<publisher-name><![CDATA[Clinicaltrials.gov]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Locametz ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Información sobre vacuna tetravalente dengue]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biswal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Borja-Tabora]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Vargas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Velásquez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Theresa-Alera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>395</volume>
<numero>10234</numero>
<issue>10234</issue>
<page-range>1423-33</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Moodie]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Juraska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Carpp]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
<name>
<surname><![CDATA[Chambonneau]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries]]></article-title>
<source><![CDATA[Trans R Soc Trop Med Hyg]]></source>
<year>2021</year>
<volume>115</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>750-63</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Pluvicto ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>octubre 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ravi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sonpavde]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jacene]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer]]></article-title>
<source><![CDATA[Expert Rev Anticancer Ther]]></source>
<year>2022</year>
<volume>3</volume>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Ficha técnica de Lupkynis®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="confpro">
<collab>EMA</collab>
<source><![CDATA[Opinión positiva de Amvuttra ®]]></source>
<year>2022</year>
<conf-name><![CDATA[ Reunión del Comité de Medicamentos de uso Humano (CHMP)]]></conf-name>
<conf-date>julio 2022</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tournev]]></surname>
<given-names><![CDATA[IL]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Planté-Bordeneuve]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of vutrisiran for patients with hereditary trnasthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial]]></article-title>
<source><![CDATA[Amyloid]]></source>
<year>2022</year>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Habtemariam]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Karsten]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Attarwala]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Goel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Melch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Clausen]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2021</year>
<volume>109</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>372-82</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
